Antiangiogeneettisillä

Antiangiogeneettisillä refers to substances or treatments that inhibit or block angiogenesis. Angiogenesis is the physiological process through which new blood vessels form from pre-existing ones. This process is crucial for normal development, such as in wound healing and the menstrual cycle, but it also plays a significant role in the growth and spread of tumors. Cancer cells often induce the formation of new blood vessels to supply themselves with the oxygen and nutrients they need to survive and proliferate.

Antiangiogeneettiset treatments aim to starve tumors by cutting off their blood supply. This is achieved by targeting molecules involved in the signaling pathways that promote blood vessel growth, such as vascular endothelial growth factor (VEGF). By inhibiting these pathways, antiangiogeneettiset drugs can slow down tumor growth, prevent metastasis (the spread of cancer to other parts of the body), and sometimes even cause existing tumors to shrink.

These therapies can be used alone or in combination with other cancer treatments like chemotherapy and radiation. While antiangiogeneettiset treatments have shown promise and have become an important part of cancer therapy for several types of cancer, their effectiveness can vary. Potential side effects are also associated with these treatments, as they can interfere with normal angiogenesis in other parts of the body. Research continues to explore new antiangiogeneettiset agents and strategies to improve their efficacy and minimize side effects.